Steatohepatitis/Metabolic Liver Disease News

WASHINGTON — In a Healio video exclusive, Leen Al-Sayyed, MD, gastroenterology and transplant hepatology fellow at St. Louis University, reported women with nonalcoholic steatohepatitis-cirrhosis had an increased prevalence for polypharmacy.

WASHINGTON — PXL065, a novel PPAR gamma-sparing chemical entity of pioglitazone, reduced liver fat content with no dose-dependent effect on weight gain in patients with nonalcoholic steatohepatitis, according to late-breaking data.

WASHINGTON — Efruxifermin improved liver histology, liver fat content and noninvasive markers of disease in patients with stage 2 or 3 fibrosis related to nonalcoholic steatohepatitis, according to late-breaking data at The Liver Meeting.

WASHINGTON — Age-standardized mortality rates for alcohol-associated liver disease and nonalcoholic fatty liver disease increased the most among the young and non-Hispanic whites, Blacks and Native Americans during the COVID-19 pandemic.

WASHINGTON — Magnetic resonance elastography was among the most accurate screening test to identify patients with at-risk nonalcoholic steatohepatitis, according to study results presented at The Liver Meeting.

WASHINGTON — Adding weight management care into a multidisciplinary nonalcoholic fatty liver disease program improved referrals for bariatric surgery at a rate of 25 times higher than the national average, according to Yale study results.

WASHINGTON — Black and Latino patients are underrepresented in cirrhosis clinical trials, underpinning the need for systematic improvement, according to research presented at The Liver Meeting.

WASHINGTON — The number of cases of alcohol-related hepatitis increased by more than 60% from 2019 to 2021 in three California hospitals, with women and young adults most affected, according to research presented at The Liver Meeting.

WASHINGTON — Children who reside in low-resource neighborhoods may be at increased risk for non-alcoholic fatty liver disease, according to study results presented at The Liver Meeting.

Obeticholic acid failed to demonstrate superiority to placebo for improving fibrosis in patients with compensated cirrhosis due to nonalcoholic steatohepatitis in a phase 3 trial, according to an Intercept Pharmaceuticals press release.